Unbiased Analysis of Today's Healthcare Issues
With co-authors Katalin Bognar, Michelle Brauer, Lauren Zhao, Rick Hockett, Michael O’Neil and Anupam Jena, I am excited to announce that our study “The potential value of rapid, cloud-enabled onsite testing for the diagnosis of rheumatoid arthritis in the United States” was published in the Journal of Medical Economics today. The full abstract is below. …
While many advancements have been made thus far in the progression toward value-based health care, there are persistent challenges in the measurement of value. In order to deliver value-based care, health care decision makers, eg, insurers and health system administrators, need value data at their fingertips—data that are relevant to their own context and reflect…
For those who are attending the International Society For Pharmacoeconomics and Outcomes Research (ISPOR) conference this next week in Baltimore, please check out my poster titled: THE EFFECT OF MEDICATION CHOICE AFTER TUMOR NECROSIS FACTOR INHIBITOR (TNFI) USE ON THE HEALTHCARE COSTS FOR PATIENTS WITH RHEUMATOID ARTHRITIS: AN INSTRUMENTAL VARIABLES APPROACH My co-authors are Ahva…
Please check out my recent paper titled “Medication Adherence Patterns Among Patients with Multiple Serious Mental and Physical Illnesses” with co-authors Joanna P. MacEwan, Alison R. Silverstein, Darius N. Lakdawalla, Ainslie Hatch and Felicia M. Forma in Advances in Health. This study is unique because it looks at medication adherence patterns among patients with…
Along with co-authors Michelle Skornicki, Michelle Brauer, Julie Villeneuve, Michael Lees, Nadine Hertel, John R. Penrod, and Jeroen Jansen, our paper “An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: Does it make a difference?” was recently published online in…
Today I participated in a fantastic panel presentation at the 2018 Academy of Managed Care & Specialty Pharmacy Conference in Boston. Moderated by Jonathan Collar of Cigna-Health Spring, the session discussed “New Tools for Measuring Treatment Value in Rheumatoid Arthritis“. My co-presenters were Jeroen Jansen from the Innovation and Value Initiative and Dr. Jeff Curtis, a…
This paper–written with co-authors Mintu P. Turakhia, Katalin Bognar, Jeffrey Trocio, Younos Abdulsattar, Daniel Wiederkehr, and Dana P. Goldman–is now up at PLOS One. The study abstract is pasted below. Introduction As atrial fibrillation (AF) is often asymptomatic, it may remain undiagnosed until or even after development of complications, such as stroke. Consequently the observed…
That is the title of my latest blog post in Health Affairs with co-author Mark Linthicum. The premise is as follows: CVS recently announced its new Transform Rheumatoid Arthritis Care initiative, which aims to reshape coverage of rheumatoid arthritis care through “value-based management strategies including outcomes based contracts and a new indication-based formulary for autoimmune…
This is the title of a recent paper by myself and co-authors Mina Kabiri, Michelle Brauer, Jeff Sullivan, Thomas M. Gill, and Dana P. Goldman published in Value in Health. The abstract of the paper is below, but do read the whole thing. Background Mobility impairments have substantial physical and mental health consequences, resulting in diminished…
That is the title of my latest article in Pharmaceutical Market Europe. An excerpt is below. Randomised controlled trials (RCTs) are regarded as the gold standard of scientific evidence, and for good reason. By randomizsing a treatment across study arms, RCTs eliminate patient-treamtent selection bias, resulting in reliable causal inference. In contrast, in the real…